



Universiteit  
Leiden  
The Netherlands

## **Iris and iridociliary melanoma : concepts in diagnosis and management**

Razzaq, L.

### **Citation**

Razzaq, L. (2011, October 11). *Iris and iridociliary melanoma : concepts in diagnosis and management*. Retrieved from <https://hdl.handle.net/1887/17921>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/17921>

**Note:** To cite this publication please use the final published version (if applicable).



## Appendix



Patient Sticker

# Appendix 1

Leiden University Medical Center, Leiden  
Department of Ophthalmology

## Guidelines for the diagnosis and treatment of iris melanoma

Doctor: ..... Date: .....

### Most Important clinical risk factors:

- |  |          |
|--|----------|
| 1. Patient has symptoms                | Yes / No |
| 2. Basal diameter of tumor > 3mm.      | Yes / No |
| 3. Abnormal tumor vessels              | Yes / No |
| 4. Pigment dispersion                  | Yes / No |
| 5. IOP > 21 mmHg                       | Yes / No |
| 6. Ectropion Uveae                     | Yes / No |
| 7. Extension to anterior chamber angle | Yes / No |
| 8. Secondary cataract                  | Yes / No |

### Prognostic Factors:

- |                             |          |
|-----------------------------|----------|
| 9. Satellite lesions        | Yes / No |
| 10. Tapioca appearance      | Yes / No |
| 11. Decreased iris motility | Yes / No |
| 12. Age > 48 years          | Yes / No |

### Examination:

- |  |          |
|--|----------|
| 1. <i>Fluorescein Angiography of Anterior Segment:</i> |          |
| a. Fluorescence completely blocked                     | Yes / No |
| b. Geographic vasculature                              | Yes / No |
| c. Early leakage                                       | Yes / No |
| d. Late leakage  | Yes / No |
| e. Abnormal vessels                                    | Yes / No |
| 2. <i>Ultrasound biomicroscopy (UBM)</i>               |          |
| i. Characteristics of iris melanoma                    | Yes / No |
| ii. Ciliary body extension                             | Yes / No |

Factors 1 – 5 Yes: 77.7% chance of having Iris melanoma; Prompt treatment

Factors 1 – 5 No: 2.3% chance of having iris melanoma; Observation

Factors: 4+6+7+8 Yes: 74.1% chance of tumor growth in 5years

Factors: 4+6+7+8 No : 1.1% chance of tumor growth in 5years

a + b Yes: Signs of benign tumor

c + d + e Yes: Signs of malignant tumor

i + ii Yes: Signs of iris melanoma

*Developed and Based on: JW Harbour, JJ Augsburger et al. Initial management and follow-up of melanocytic iris tumors. Ophthalmology, 1995(102): 1987-1993; van Klink F., de Keizer RJ, Jager MJ, Kakebeke-Kemme HM. Iris nevi and melanomas: a clinical follow-up study. Doc.Ophthalmol. 1992;82:49-55.*

## Appendix 2

University Medical Center, St. Radboud, Nijmegen

Leiden University Medical Center, Leiden

Patient Sticker

Department of Ophthalmology

### Ultrasound biomicroscopy (UBM) characteristics for the diagnosis of iris melanoma

Doctor: ..... Date: .....

#### UBM Characteristics favoring the diagnosis of iris melanoma:

- |   |          |
|---|----------|
| 1. Largest basal tumor dimension > 3mm              | Yes / No |
| 2. Tumor thickness > 1mm                            | Yes / No |
| 3. Irregular tumor structure                        | Yes / No |
| 4. Indistinct tumor boundary with irregular outline | Yes / No |
| 5. Secondary iris pigment epithelium cysts          | Yes / No |
| 6. Non-intact posterior iris pigment epithelium     | Yes / No |
| 7. Low internal reflectivity                        | Yes / No |
| 8. Ciliary body extension                           | Yes / No |
| 9. Tumor extension to anterior chamber angle        | Yes / No |

*Based on UBM schedule developed by Dr. A.M. Verbeek  
University Medical Center, St. Radboud, Nijmegen.*

Patient Sticker

## Appendix 3

Leiden University Medical Center  
Department of Ophthalmology

### New modified guidelines for the diagnosis and treatment of iris melanoma

Doctor: ..... Date: .....

#### Clinical Risk factors:

- |                                   |          |
|-----------------------------------|----------|
| 1. Symptoms                       | Yes / No |
| 2. Basal diameter of tumor > 3mm. | Yes / No |
| 3. IOP > 21 mmHg                  | Yes / No |
| 4. Secondary cataract             | Yes / No |
| 5. Age > 48 years                 | Yes / No |

Clinical risk factors 1- 5 Yes: 99.31 % probability of having melanoma

Clinical risk factors 1- 5 No: 0.69 % probability of having melanoma

#### UBM Characteristics:

- |                                     |          |
|-------------------------------------|----------|
| 1. Tumor thickness > 1mm.           | Yes / No |
| 2. Basal tumor diameter > 3mm.      | Yes / No |
| 3. Low reflectivity                 | Yes / No |
| 4. Anterior chamber angle extension | Yes / No |
| 5. Secondary iris cysts             | Yes / No |

UBM characteristics 1- 5 Yes: 99.76 % probability of having melanoma

UBM characteristics 1- 5 No: 0.24 % probability of having melanoma

For the other possible combinations of positive and negative factors, probability of having melanoma can be computed on the basis of formula given in next pages.

*Based on the results of study described in chapter 2 of this thesis (October 2011).*

**Formula for computing probability of having iris melanoma on the basis of clinical risk factors:**

$$1/(1+\exp(-6.496 + 1.965 \times \text{complaints} + 3.007 \times \text{diameter} + 3.145 \times \text{IOP} + 2.666 \times \text{Secondary cataract} - 1.33 \times \text{age} ))$$

Variable		Parameter coding
Symptoms	No	1
	Yes	0
Diameter > 3mm	No	1
	Yes	0
IOP > 21mmhg.	No	1
	Yes	0
Secondary cataract	No	1
	Yes	0
Age > 48	No	1
	Yes	0

Risk factor	B
complaints	-1.965
Diameter	-3.007
IOP	-3.415
Secondary cataract	-2.666
Age	1.330
Constant	6.496

For example, if a patient has symptoms and the diameter of lesion is > 3mm: then these two factors has parameter coding '0' for Yes.

All other factors are '1' for No, as given in coding table.

Then above formula becomes:

$$1/(1+\exp(-6.496 + 0+0 + 3.145 \times 1 + 2.666 \times 1 - 1.33 \times 1)) = 0.88$$

It means that probability of having melanoma is 88%

**Formula for computing probability of having iris melanoma on the basis of UBM characteristics:**

$1/(1+\exp(-7.001 + 3.377 \times \text{thickness} + 1.753 \times \text{diameter} + 1.607 \times \text{iris cysts} + 2.093 \times \text{reflectivity} + 4.175 \times \text{AC extension}))$

		Parameter coding
AC angle extension	No	1
	Yes	0
Thickness	< 1mm	1
	> 1mm	0
Diameter	< 3mm	1
	> 3mm	0
Iris cysts	No	1
	Yes	0
Reflectivity	High	1
	Low	0

Risk Factor	B
Thickness	-3.377
Diameter	-1.753
Iris cysts	-1.607
Reflectivity	-2.093
AC angle extension	-4.175
Constant	7.001

For example, if a patient has thickness > 1mm and diameter of lesion > 3mm. on UBM, then these two factors has parameter coding '0' for Yes and all other factors are '1' for No, as given in coding table.

Above formula then becomes:


$$1/(1+\exp(-7.001 + 0 + 0 + 1.607 \times 1 + 2.093 \times 1 + 4.175 \times 1)) = 0.77$$

It means that probability of having melanoma is 77%




## Appendix: Figures


**Figure 1** Ruthenium CIA plaque designed for iris melanoma



**Figure 2** Few study patients with iris melanoma treated with Ruthenium plaque therapy. Left side 3 pictures showing tumor before treatment, Right side the same tumors after the treatment



**Figure 3** A: One study patient having iris melanoma in inferotemporal quadrant of right eye before treatment B: Same iris melanoma one year after treatment with Ru-106. C: After 3 years patient showed recurrent tumor and extrascleral extension. D: Histology of irradiated area showing viable cells. The chamber angle is closed by fibrosis and covered with a thin layer of vital un-pigmented melanoma cells. (original magnification: x10) E: Histology showing melanoma cells on the iris surface, in the opposite chamber angle, in the trabecular meshwork and extrascleral extension. (original magnification: x2.5).









## **Acknowledgements**



## Acknowledgements

Another milestone in my life: PhD Ophthalmology, which owes recognition, after Almighty Allah (the most merciful, the most beneficial), to many whose help, guidance and encouragement made it happen. I am indebted to all of them for reasons best known to them.

I should start with acknowledgement for the Higher Education Commission (HEC) of Pakistan for awarding me with the PhD scholarship and for Netherlands Organization for International Cooperation in Higher Education (NUFFIC) for managing my scholarship. Thanks to Prof. Dr. Farooq Afzal, Professor of Ophthalmology at the Pakistan Institute of Medical Sciences (PIMS), Islamabad, for his valuable guidance and supervision during my ophthalmic training.

From December 2007, with the move to the Netherlands to start my PhD study, our lives took a big turn and I like to thank all the colleagues and staff at the department of Ophthalmology of the LUMC for making this turn the RIGHT turn.

I have utmost gratitude for Prof. Dr. Grè Luyten for providing me the opportunity to start this PhD project, for his constant advice and new ideas for research. Your interest shown in the progress of this thesis has been always the source of encouragement. We can never forget your and Mrs. Yolanda's warmth and hospitality at your home around our first freezing Christmas days in Netherlands.

I am greatly indebted to my supervisor, Prof. Dr. Rob de Keizer, for his esteemed guidance during these four years and for showing confidence in my work capacities. Thank you for your support academically and well beyond academics, your encouragement, patience, long fruitful discussions, expertise and in-depth knowledge. And how I can forget Mrs. Mariam de Keizer for her affection for me and my family.

I want to thank Prof. Dr. Nicoline Schalij-Delfos for her contribution to chapter 7 of this thesis and the support beyond this thesis.

I also express my sincere thanks to Prof. Caesar Sterk and Mrs. Ine Sterk for their help and care with our settlement in The Netherlands. I always enjoyed the non-ophthalmic discussions with you in the corridors and impressed by your knowledge on every subject. I like to thank Dr. Didi Wolff-Rouendaal for answering my first mail sent to the LUMC on starting PhD study, for putting me on the right path, introducing me with the subject of Ophthalmic Pathology and for being so kind always.

Dr. Martine Jager, without mentioning your name this page would be incomplete. Your care, support, encouragement, guidance and detailed feedback in all the aspects of my study and stay in The Netherlands can never be forgotten. Even more, your guidance to my husband's career promotion and your care for my



boys is deeply relished. I wish from the depth of my heart that the future brings you more happiness and success.

Dr. Marinkovic, Marina. I appreciate your friendship, your ocular oncology teaching, subject related discussions and the gossips which we shared over the last 4 years. Your support and encouragement made me go through some tough situations. I wish you all the success in life and hope to come again to Netherlands at your PhD defense.

I am grateful to the Ocular Oncology clinic team, in addition to Prof. Luyten and Dr. Marinkovic, Dr. Bleeker and Mw. Joke van der Berg, for their support.

I want to thank all ophthalmologists at the Ophthalmology department of the LUMC: Dr. Jan Geert Bollemeijer for his kind smile always and cricket discussions, Dr. Wouter Swart for teaching me the basics of ophthalmic ultrasound, Dr. Greetje Dijkman for giving me the opportunity to get some experience in the subject of medical retina, Dr. Mariëtta Swart, Dr. Irene Notting and Dr. Barbara Haeseker.

Thanks to all the colleagues at the Ophthalmology lab, especially Dr. Mieke Versluis and Dr. Pieter van der Velden for supporting and bearing me without any prior knowledge of lab work during our last research project. Thanks to all the residents, in particular Willem Maat, Sander Keijser and Long Ly for their help whenever it was needed. I would specifically like to thank Katinka, Ellen, and Monique from the photo department, for their support from the very initial days. Marjolijn, for her spirit and enthusiasm, Yvonne and all the nurses for their help. All the ladies at the reception desk of Ophthalmology: Nen, Gera, Els, Indira, Annemarie, Antoinette were always so kind to me in searching of patients records needed for my research. Special thanks to the Oculenti and Orthoptist teams for the help which I needed for my FRCS exam. I appreciate the help of Cora, Judith and Sylvia for all my research work.

I am thankful to the secretaries Marja, Angeline, Rineke, Katja and Eva for their enormous help in daily issues all the way and providing me a wonderful company.

Aty van der Leden, *mijn Nederlandse moeder*, you were the first one to help me and to manage all the affairs even before my arrival in Leiden, and you remained available throughout even after leaving ophthalmology department. I am thankful for your love and care not only for me but also for my family which made our stay in The Netherlands a memorable period of our lives. Special thanks for translating my thesis discussion into Dutch. I love you and wish you and Wim a very happy healthy life together.

I am also indebted to Prof. Dr. Saskia Imhof and Dr. Annette Moll for making it possible for me to attend the Retinoblastoma clinics in the VU Medical Center in Amsterdam regularly. I am much obliged to Dr. Annette and Dr. Machteld

Bosscha for giving me the opportunity to participate in Retinoblastoma research and for their hospitality during the manuscript discussions. I also want to say thanks to Tamara Marees, Annelies Frankfoorder and Gerda Buurmans for their support during my VUMC visits.

I am thankful to the colleagues from the department of Clinical Oncology, Dr. Carien Creuzberg and Dr. Martijn Ketelaars for their collaboration on studies presented in chapter 7 and 9 in this thesis. Dr. B.M. Verbist, Prof. Dr. M.A. van Buchem and Prof. Dr. A. Webb are acknowledged for their collaboration in the on-going research projects of MRI.

I must not forget to thank Mrs Margot Vianen, HRM-assistant of division 3, for always helping to find solutions in the jungle of regulations. I would like to thank all my study patients for making my research possible. Acknowledgements to the organizations that supported my research financially, without that it would not have been possible.

A special thank you to all our friends in The Netherlands: Dutch and Pakistani for helping and supporting. I really appreciate all the Pakistani scholars and their families for providing company, wonderful gatherings and delicious cooking and dinners and even taking care of our kids.

I am also grateful to the members of the promoting committee for evaluating my thesis manuscript.

On a personal note, I would like to thank my family for all their support. My in-laws: especially my parents-in-law, for always standing with me, my brother-in-law Sulman for his technical help for this thesis in spite of being far away. My one and only sister Dr. Asma, *Api*, without you my achievements are incomplete, her husband and my brother-in-law Dr. Waqar, you were always there as a brother whenever i needed, your support matters a lot.

I owe this achievement to my parents: my father, *Abu*, your devotion to your daughters' education and your prayers, made it all happen. My mother, *Mama*, your love and dedication to your children, sometimes even at the cost of your health, is deeply relished.

Finally to the keeper of the key to my heart, my husband Burhan, your sacrifices for my career, your care, love and support motivated me to pursue. You are the passion of my life.

My sons Mohid and Mahad, I still feel so guilty for those 3 months when I came here without you. Your hugs, kisses and cheers always made me forget the stresses of life, no matter how big they were. You gave up countless evenings, weekends and vacations with mama so that this dream could become a reality. This all is for you.....





## **List of Publications**



## List of publications

### **Ruthenium plaque radiation for iris and iridociliary melanomas: development of dry eyes?**

Razzaq L, de Keizer RJ

*Br J Ophthalmol.* 2010 Nov; 94: 1549-50. Published online: 2010 June 1.

### **Ruthenium plaque radiation therapy for iris and iridociliary melanomas**

Razzaq L, Keunen JEE, Schalijs-Delfos N, Creutzberg CL, Ketelaars M, de Keizer RJ

*Acta Ophthalmol.* 2010 Jul 29. [Epub ahead of print]

### **Iris melanoma in a child treated with iridectomy and a phakic iris repair implant lens: a case report of 8 years postoperative follow-up**

de Keizer RJ, Razzaq L, Tassignon MJ, Verbeek AM

*Br J Ophthalmol.* 2010 Jul; 94(7):953-4.

### **Anterior segment imaging of iris melanocytic lesions**

Razzaq L, Van der Spek KE, Luyten GPM, de Keizer RJ

*Eur J Ophthalmol.* 2011 Sep-Oct ;21(5):608-14.

### **Transscleral excision of suprauveal mesectodermal iridociliary leiomyoma Without postoperative iris defect: Correlation with UBM, MRI and histopathology**

Razzaq L, Semenova EA, Marinkovic M, de Keizer RJ, Van Duinen SG, Luyten GPM.

Accepted in *Arch of Ophthalmol.* 2011 Feb.

### **Clinical and pathologic characteristics of biopsy proven iris melanoma: A multicenter international study**

Khan S, Finger PT, Yu G, Razzaq L, Jager MJ, de Keizer RJW, Sandkull P, Seregard S, Gologorsky D, Scheffler AC, Murray TG, Kivela T, Giuliari GP, McGowan H, Simpson ER, Corriveau C, Coupland SE, Damato BE

*Arch of Ophthalmol.* Published online September 12, 2011.

### **Guidelines for diagnosis and treatment decision of suspected iris and iridociliary melanomas based on clinical risk factors and ultrasound biomicroscopic characteristics**

Razzaq L, Keunen JEE, van Zwet EW, Luyten GPM, de Keizer RJ.

Submitted.

**Corneal endothelial cell density after Ruthenium plaque radiation therapy for iris melanoma patients**

Razzaq L, Jager MJ, Luyten GPM, Marinkovic M, de Keizer RJ

*Submitted.*

**Fuchs adenoma of the choroid simulating a choroidal hemangioma**

Razzaq L, Marinkovic M, Swart W, van Duinen SG, Luyten GPM.

*Submitted.*

**Incidence of retinoblastoma in the Netherlands 1950 - 2010: A shift in the proportion of hereditary retinoblastoma**

Bosscha MI, Razzaq L, Dommering CJ, van Leeuwen FE, Moll AC

*Submitted.*

**Changes in contrast sensitivity functions and visual acuity in patients with pre-senile and senile cataract**

Razzaq L, Afzal F.

*Dissertation accepted by College of Physicians and Surgeons, Karachi, Pakistan.*

*2009 Aug.*

**The BRAF, GNAQ and GNA11 mutations in iris melanomas and histopathological correlation**

Razzaq L, Versluis M, Jager MJ, Luyten GPM, de Keizer RJW, van der Velden PA.

*Manuscript in preparation.*









## **Curriculum Vitae**



## Curriculum Vitae

The author of this thesis, Lubna Razzaq, was born on September 29th, 1975 in Islamabad, Pakistan. She completed her secondary school education at the Federal School and College Islamabad, standing first in her college and 5th in the Federal Board of secondary education in 1993. She received her Bachelors in Medicine and Bachelors in Surgery (MBBS) degree in 1999 from Rawalpindi Medical College, Rawalpindi, Pakistan, securing the position among the top ten of 250 students. While attending the eye ward during her medical school, she observed how small procedures, such as cataract surgery, bring big changes in one's life; she therefore opted for Ophthalmology as her future field. She passed her Fellowship part 1 Ophthalmology examination in 2000. In 2001, after passing the Federal Public Service Commission Examination, she became Registrar in Ophthalmology. Initially, she worked at the Jinnah Postgraduate Medical Center, Karachi (2001- 2002) and then at the Pakistan Institute of Medical Sciences, Islamabad, Pakistan (2003-2007), where she completed her ophthalmic training. In December 2007, she began her PhD study on ocular melanomas under the supervision of Professor Dr. Gré P.M. Luyten and Prof. Dr. Rob J.W. de Keizer at Leiden University Medical Center, the Netherlands. During her research, she also had the opportunity to increase her clinical knowledge and skills in Ocular Oncology. Meanwhile, she passed the Fellowship of the Royal College of Surgeons in Ophthalmology, Edinburgh, United Kingdom, Part 1 & 2 in 2009 and Part B (7 of 8 sections) in June 2011. The results of her PhD research are presented in this thesis. After finishing her PhD, she is going to start working as clinical ophthalmologist.

Besides working in Ophthalmology, she is the wife of Burhan-ud-din Qureshi and the mother of two sons, Mohid and Mahad.





